Abstract
Testational trophoblastic neoplasia includes invasive mole, choriocarcinoma, and placental site trophoblastic tumor. The overall care rate in the treatment of these tumors currently exceeds 90%. This success is the result of the inherent chemotherapy sensitivity of trophoblastic neoplasms, the effective use of the tumor marker human chorionic gonadotropin (hCG) for diagnosis of disease and monitoring of therapy, the referral of patients to or consultation with specialized treatment centers, the identification of prognostic factors that enhance individualization of therapy, and the development of active combinations of chemotherapy agents used in conjunction with irradiation and surgery to treat patients with the most advanced disease.
| Original language | English (US) |
|---|---|
| Title of host publication | Oncology |
| Subtitle of host publication | An Evidence-Based Approach |
| Publisher | Springer New York |
| Pages | 899-909 |
| Number of pages | 11 |
| ISBN (Print) | 0387242910, 9780387242910 |
| DOIs | |
| State | Published - 2006 |
ASJC Scopus subject areas
- General Medicine
